ACHP Statement on Drug Pricing
ACHP released a statement on drug pricing.
04/18/2025
Anticompetitive practices within the pharmaceutical industry, coupled with outdated patent laws that inhibit more affordable biosimilars and generics, have resulted in skyrocketing drug costs for all Americans – but especially seniors and those with chronic conditions. ACHP advocates for sensible policies such as price transparency to rein in sky-high costs so that patients can afford the medications they need.
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad …
04/10/2025
ACHP President and CEO Ceci Connolly released a statement in …
04/04/2025
ACHP sent a letter to CMS Administrator, Dr. Oz, with …
04/04/2025
ACHP is grateful for its longstanding partnership with CMS and …
04/03/2025
ACHP President and CEO Ceci Connolly coauthored an op-ed examining …
04/10/2024
Transparency in the drug supply chain is desperately needed to …
03/24/2025
When people with diabetes follow their prescribed medical regimens, they …
11/10/2023
Morgan Health CEO Dan Mendelson joins the Healthy Dialogue podcast …
09/13/2022
ACHP applauds the Senate for passing the Inflation Reduction Act, …
08/07/2022
The Alliance of Community Health Plans has sent Congressional Leaders …
04/25/2022
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad …
04/10/2025
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad dominance. Patients should be able to access affordable, necessary medications, rather than being swayed by misleading marketing tactics.
04/10/2025
ACHP sent a letter to Dr. Mehmet Oz with commonsense reforms that cut unnecessary red tape and save precious health care dollars.
04/10/2025
ACHP comments on the CMS Marketplace Integrity and Affordability Proposed Rule.
04/10/2025
ACHP commends the Trump Administration for finalizing policies in the 2026 MA and Part D Rate Notice that reflect higher care delivery costs and for taking another step toward reining …
04/07/2025